top of page
検索

Pfizer licenses Starna Therapeutics' in vivo CAR-T programmes in deal worth up to $2.63 billion

執筆者の写真: nuaxia
nuaxia
1 日前
読了時間: 2分

Pfizer has secured rights to three preclinical in vivo CAR-T programmes from Starna Therapeutics through a licensing agreement featuring $330 million upfront and up to $2.3 billion in contingent milestone payments.


Pfizer announced on 18 November 2026 that it had entered into an exclusive licensing agreement with Starna Therapeutics covering three preclinical in vivo CAR-T programmes targeting autoimmune diseases, alongside broader technology rights spanning immunology and oncology.


The agreement provides Starna with $330 million upfront and eligibility for up to $2.3 billion in development and commercial milestones plus royalties, with Pfizer leading clinical development outside Greater China; the approximately $2.63 billion maximum potential consideration excludes royalties, is not guaranteed and concerns programmes that remain pre-IND rather than approved treatments.

Field

Content

Licensing Company

Pfizer

Partner Company

Starna Therapeutics

Announcement Date

18 November 2026

Agreement Type

Exclusive licensing agreement

Technology

In vivo chimeric antigen receptor T-cell (CAR-T) therapy

Licensed Programmes

Three preclinical in vivo CAR-T programmes

Primary Therapeutic Focus

Autoimmune diseases

Additional Technology Rights

Immunology and oncology

Development Stage

Preclinical and pre-IND

Geographic Rights

Principal licensed territories outside Greater China with options to expand rights

Development Responsibilities

Pfizer to lead clinical development outside Greater China

Upfront Payment

$330 million

Potential Milestone Payments

Up to $2.3 billion in development and commercial milestones

Maximum Potential Deal Value

Approximately $2.63 billion excluding royalties

Additional Consideration

Royalties on applicable future commercial sales

Deal Significance

Expands Pfizer's in vivo cell therapy capabilities; milestone payments are contingent and no licensed programme is approved

Primary Source

https://www.pfizer.com/news/press-release/press-release-detail/pfizer-enters-exclusive-licensing-agreement-starna


Discover how nuaxia can support your next medical education initiative:

 
 
 

コメント

5つ星のうち0と評価されています。
まだ評価がありません

評価を追加
bottom of page